ARTICLE | Company News
Marketing clearance for UroVysion
August 2, 2001 7:00 AM UTC
Vysis (VYSI) received FDA marketing clearance for its UroVysion fluorescent DNA probe assay to test for recurrence of bladder cancer by detecting chromosomal abnormalities in bladder cells. The test w...